CODX news

Co-Diagnostics, Inc. announced a $2.1 million senior secured convertible note issuance, with principal repayments scheduled in 30 weekly installments starting October 14, 2026. This financing underscores the company's efforts to secure capital despite current market conditions.

The company reported strong financial results driven by its mPCR platform, though it provided lower than expected fiscal 2025 revenue guidance.

Co-Diagnostics and ReadyGo are collaborating to evaluate ReadyGo's blood sample prep technology with Co-Dx PCR platform for decentralized Ebola detection, potentially expanding the platform to other bloodborne pathogens like HIV and Hepatitis.

Co-Diagnostics Inc. has entered into a placement agency agreement with Maxim Group LLC. Under this agreement, Maxim will act as the exclusive placement agent to sell Common Stock, Pre-Funded Warrants, and Common Warrants directly to investors as induced exercises of existing warrants. The transactio…

Co-Diagnostics issued pre-funded warrants exercisable for common stock starting May 21, 2026, under a securities purchase agreement dated May 19, 2026. The warrants were issued in an unregistered offering relying on exemptions from SEC registration requirements.